Doubly modified soya enters Europe
Enlarge image


Doubly modified soya enters Europe

10.07.2012 - The European Commission has authorised the import of Monsanto’s soya which bears additional genes for a herbicide tolerance and an insecticide.

Just a few days after the European Food Safety Authority (EFSA) had approved the cultivation of genetically modified (GM) soya on European soils, the European Commission agreed on another soya matter. On 27 June, without public communication, the Commission authorised Monsanto Company’s genetically engineered soya Intacta RR2 Pro for import to the European Union. These soya plants harbour a combination of gene constructs that convey both tolerance for herbicides and resistance to insects. More specifically, Intacta is a combination of soys MON87701 and MON89788 which produce an insecticidal Bt protein and is tolerant to the herbicide glyphosate, respectively. It is the first time in the EU that gm-soya with stacked gene constructs has been allowed for usage in food and feed.

On 6 July the Brazilian Association of Seeds and Seedlings (ABRASEM) issued a statement „celebrating the opening of new doors to varieties of high technology seeds.“ Brazil is the main beneficiary of the authorisation as Monsanto’s soya is grown and harvested there. Europe is the second main destination of Brazilian soya exports, with China leading the chart. However, Intacta is not yet approved by China so that the European decision could very well be interpreted as trend-setting.


12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK40.4%
  • ZEALAND PHARMA (DK)160.00 DKK31.1%
  • THROMBOGENICS (B)3.98 EUR30.1%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5137.5%
  • CHRONTECH PHARMA (S)0.34 SEK466.7%
  • GALAPAGOS (B)38.68 EUR247.8%


  • NEOVACS (F)0.75 EUR-76.1%
  • BIOTEST (D)19.54 EUR-72.9%
  • EVOCUTIS (UK)0.15 GBP-68.7%

No liability assumed, Date: 12.10.2015